Bank sues analyst. (DealBreaker.com, Big Picture, ClusterStock.com)
Recent changes in asset class correlations. (Bespoke Investment Group)
The Roche-Genentech deal is going to be a “an expensive, time-consuming affair”. (Deal Journal)
Two different approaches, two different results: InBev and Microsoft. (DealBook)
What can Microsoft (MSFT) do about its languishing stock price? (Tech Trader Daily)
Some hedge fund stars from 2007 are having a repeat performance in 2008. (WSJ.com)
An obscure market timing indicator turns positive for the first time in a while. (Marketwatch.com)
Ten new international sector ETFs. (24/7 Wall St.)
There is nothing magical about the VIX. (Daily Options Report)
It has been a really bad quarter for dividends. (MarketBeat)
Not all financials are ‘poison.’ (Aleph Blog)
Data on ‘naked shorts‘ is hard to come by. (NakedShorts)
Traders need to deal with “should-have syndrome.” (TraderFeed)
An interesting job post for a hedge fund. (Infectious Greed)
The CBO weighs in on the GSE rescue plan. (Odd Numbers, Curious Capitalist)
What is causing global food inflation? (Economist’s View)
Are you a fan of Abnormal Returns? Check. Prefer to read our posts via e-mail? Check. A simple sign-up form to receive all of our posts in your inbox. Check.